Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.13

+0.88%
HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$3.51B
EPS-4.2000
P/E Ratio-20.03
Earnings Date08/06/2026

dnth

Total Other Income Expenses Net

Last Annual Value

15.60M

3-Year CAGR

133%

5-Year CAGR

33%

10-Year CAGR

58%

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Competitors Analysis of Total Other Income Expenses Net

DNTH · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.60M
50.0%N/AN/A 
11.78M
446.9%N/AN/A
ANAB logo
AnaptysBio, Inc.
NASDAQ:ANAB
-60.96M
N/AN/AN/A
-33.44M
N/AN/AN/A
15.96M
10.2%273.4%N/A
-53.21M
N/AN/AN/A
16.52M
71.3%N/AN/A
1.50M
N/AN/AN/A
-560.09M
N/AN/AN/A
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Fair Value Envelope

DNTH · NASDAQ

Our analysis suggests that DNTH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.13, this represents a potential HIDDEN relative to our calculated worth for Dianthus Therapeutics, Inc..

Intrinsic Value
Current Price: $84.13